On December 17 local time, MilliporeSigma, the life sciences business unit of German pharmaceutical and chemical giant Merck Group, announced that it would complete the acquisition of HUB Organoids, an internationally recognized pioneer in organoid research and development, by the end of 2024. This has undoubtedly created a huge stir in the organoid market.Officials said that through this acquisition, Merck aims to expand its portfolio of 2D and 3D cell culture products. As the fastest - growing area in cell culture, organoids have the potential to accelerate drug development and reduce animal testing.Jean - Charles Wirth, Head of Science and Laboratory Solutions at Merck Life Science, said, "For researchers committed to adopting new approaches to treat today's most challenging diseases, organoids provide important insights into biological systems. We look forward to enabling scientists to obtain solutions from samples more quickly and conveniently."The application prospe...

On October 10, 2024, the Center for Drug Evaluation (CDE) of the National Medical Products Administration released the "Notice on Soliciting Opinions on the Technical Guidelines for Model - Guided R & D of Rare Disease Drugs (Draft for Comment)". The draft clearly states that due to the particularity nature of rare diseases, non - clinical research data in the R & D of rare disease drugs include, but are not limited to, gene, molecular, cell, organoid, organ - on - a - chip, and animal research data. It also emphasizes that the basis for dose selection in clinical research can be derived from animal research and /or in - vitro research results such as organoids and molecules.Jiyan Biotech positions itself in the field of precision oncology medical services. It focuses on the construction of tumor organoid models and the development of organ - on - a - chip technology platforms, which are applied to drug sensitivity testing, drug evaluation, research on potential targe...